REPL

5.09

3.05% -0.16

Handel nachbörslich: 5.24 0.15 +2.95%

Replimune Group Inc (REPL)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$5.25

Offen:

$5.34

24-Stunden-Volumen:

3.28M

Relative Volume:

0.42

Marktkapitalisierung:

$397.30M

Einnahmen:

Nettoeinkommen (Verlust:

$-209.96M

KGV:

-1.6108

EPS:

-3.16

Netto-Cashflow:

$-176.27M

1W Leistung:

-7.45%

1M Leistung:

-53.60%

6M Leistung:

-64.38%

1J Leistung:

-47.69%

1-Tages-Spanne:

$5.08

$5.376

1-Wochen-Bereich:

$4.49

$5.5599

52-Wochen-Spanne:

$2.68

$17.00

Replimune Group Inc Stock (REPL) Company Profile

Firmenname

Replimune Group Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (646)

Telefon

(781) 222-9600

Adresse

500 UNICORN PARK, WOBURN, MA

Mitarbeiter

479

Twitter

@Replimune

Nächster Verdiensttermin

2025-02-11

Neueste SEC-Einreichungen

REPL's Discussions on Twitter

Vergleichen Sie REPL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
REPL Replimune Group Inc	5.09	409.79M	0	-209.96M	-176.27M	-3.16
VRTX Vertex Pharmaceuticals Inc	395.92	99.42B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	561.55	58.99B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	432.52	56.35B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	646.60	39.02B	3.05B	1.28B	-614.78M	19.58
ONC Beone Medicines Ltd Adr	307.51	34.25B	3.81B	-644.79M	-669.77M	-6.24

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-30	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2025-07-23	Herabstufung	BMO Capital Markets	Outperform → Underperform
2025-07-23	Herabstufung	Barclays	Overweight → Equal Weight
2025-07-23	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-07-22	Herabstufung	JP Morgan	Overweight → Neutral
2025-07-22	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-07-22	Herabstufung	Piper Sandler	Overweight → Neutral
2025-07-22	Herabstufung	Wedbush	Outperform → Neutral
2025-06-20	Eingeleitet	Cantor Fitzgerald	Overweight
2024-08-28	Eingeleitet	ROTH MKM	Buy
2023-04-17	Fortgesetzt	Piper Sandler	Overweight
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-10-15	Fortgesetzt	BTIG Research	Buy
2020-11-17	Eingeleitet	BTIG Research	Buy
2020-11-02	Eingeleitet	Jefferies	Buy
2020-10-15	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-07-01	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-05-05	Eingeleitet	Barclays	Overweight
2019-09-04	Eingeleitet	ROTH Capital	Buy
2019-07-23	Eingeleitet	Chardan Capital Markets	Buy
2019-07-12	Hochstufung	JP Morgan	Neutral → Overweight
2019-07-08	Eingeleitet	H.C. Wainwright	Buy
2019-04-25	Eingeleitet	Wedbush	Outperform
2019-01-23	Herabstufung	JP Morgan	Overweight → Neutral
2018-08-14	Eingeleitet	JP Morgan	Overweight
2018-08-14	Eingeleitet	Leerink Partners	Outperform

Alle ansehen

Replimune Group Inc Aktie (REPL) Neueste Nachrichten

03:39 AM

Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky - TradingView

03:39 AM

03:29 AM

Shareholders who lost money on Replimune Group, Inc. - GlobeNewswire

03:29 AM

02:45 AM

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Altimmune, Inc. (ALT) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - GlobeNewswire Inc.

02:45 AM

01:41 AM

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire

01:41 AM

12:15 PM

Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire

12:15 PM

12:06 PM

Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 - ACCESS Newswire

12:06 PM

Aug 12, 2025

REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit - Morningstar

Aug 12, 2025

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire

Aug 12, 2025

Aug 11, 2025

Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire

Aug 11, 2025

Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - GlobeNewswire Inc.

Aug 11, 2025

Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire

Aug 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire

Aug 11, 2025

Class Action Filed Against Replimune Group, Inc. (REPL)September 22, 2025 Deadline to JoinContact The Gross Law Firm - PR Newswire

Aug 11, 2025

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire

Aug 11, 2025

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - Morningstar

Aug 11, 2025

Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Aug 11, 2025

Investors in Replimune Group, Inc. (REPL): Protect Your RightsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire

Aug 11, 2025

Aug 10, 2025